Stifel lowered the firm’s price target on Bruker (BRKR) to $48 from $57 and keeps a Hold rating on the shares. Bruker had pre-announced the quarter, but “as many had expected,” the company’s view on 2025 growth has come in on worsening academic trends and tariff impacts. The resulting guidance positions growth to be flattish this year, but “that hopefully also sets a floor for earnings,” the analyst tells investors in a post-earnings note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target lowered to $46 from $50 at Barclays
- Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges
- Bruker Corporation Reports Strong Q1 2025 Revenue Growth
- Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties
- Bruker Corporation Navigates Growth Amidst Challenges